Treatment of Suspected Melioidosis

Initial Intensive Phase Treatment

• The American College of Physicians recommends treatment with intravenous meropenem or imipenem for at least 14 days for suspected melioidosis due to VITEK misidentification of Burkholderia pseudomallei, with demonstrated better clinical outcomes than ceftazidime in severe melioidosis cases 1, 2, 3
• The Infectious Diseases Society of America suggests that carbapenems, such as meropenem or imipenem, are the preferred treatment option for severe cases of melioidosis, with all clinical B. pseudomallei isolates showing consistent susceptibility to carbapenems 1, 2, 3
• Ceftazidime is an alternative treatment option, with a recommended dosage of 100 mg/kg/day for at least 14 days, and may be used if carbapenems are not available 2, 3, 4

Eradication Phase Treatment

• The Centers for Disease Control and Prevention recommends trimethoprim-sulfamethoxazole (TMP-SMX) as the standard treatment for the eradication phase, with a duration of 3-6 months and a standard dosing of double-strength tablet (160 mg trimethoprim/800 mg sulfamethoxazole) twice daily 2, 4
• Alternative treatments for the eradication phase include amoxicillin-clavulanate and doxycycline, which may be used if TMP-SMX is not tolerated or contraindicated 2, 3, 4

Special Considerations

• B. pseudomallei is inherently resistant to many antibiotics, including penicillin, ampicillin, first- and second-generation cephalosporins, gentamicin, streptomycin, and polymyxin, according to the World Health Organization 1, 4
• The European Centre for Disease Prevention and Control suggests that selective culture media, such as Ashdown's agar, can significantly increase the yield of B. pseudomallei from clinical specimens and is highly cost-effective in endemic areas 5
• Delays in appropriate therapy can lead to poor outcomes, and treatment should be continued until confirmation by more reliable methods, as recommended by the International Society for Infectious Diseases 5

Melioidosis Management

Initial Intensive Phase Treatment

• For severe melioidosis, carbapenems demonstrate superior clinical outcomes compared to ceftazidime, with meropenem or imipenem as the preferred first-line agents, and treatment should continue for at least 14 days, but extend treatment duration for patients with critical illness, extensive pulmonary disease, deep-seated abscesses, osteomyelitis, septic arthritis, or neurologic involvement 6
• Ceftazidime remains an acceptable alternative if carbapenems are unavailable, though observational data suggest meropenem achieves better clinical outcomes in severe disease 6

Important Resistance Patterns

• B. pseudomallei is inherently resistant to penicillin, ampicillin, first- and second-generation cephalosporins, gentamicin, streptomycin, polymyxin, ertapenem, azithromycin, and moxifloxacin 6
• Avoid ceftriaxone and cefotaxime, as these agents are associated with higher mortality rates compared to ceftazidime 6

Eradication Phase Treatment

• TMP-SMX monotherapy for 20 weeks is as effective as combination therapy with TMP-SMX plus doxycycline in preventing recurrence 6
• The 3-6 month duration is critical for eradicating intracellular bacteria and preventing the 13% relapse rate seen over 10 years 6

Alternative Eradication Regimens

• Amoxicillin-clavulanate is the preferred alternative for pregnant women, children, or patients intolerant to TMP-SMX, though it is significantly less effective than first-line therapy 7, 6
• Doxycycline can be used as an alternative if TMP-SMX is contraindicated 6

Post-Exposure Prophylaxis

• Administer TMP-SMX (co-trimoxazole) within 24 hours of exposure for post-exposure prophylaxis, particularly for immunosuppressed patients or following potential biological attack 7

Bactrim DS Dosing for Melioidosis

Weight-Based Dosing Recommendations

• For adults weighing <40 kg, the recommended dose is 160/800 mg (1 DS tablet) twice daily, for adults weighing 40-60 kg, the recommended dose is 240/1200 mg (1.5 DS tablets) twice daily, and for adults weighing >60 kg, the recommended dose is 320/1600 mg (2 DS tablets) twice daily, according to the Journal of Microbiology, Immunology and Infection 8
• Folic acid 0.1 mg/kg up to 5 mg daily should be added to prevent antifolate effects without compromising antimicrobial activity, as recommended by the Journal of Microbiology, Immunology and Infection 8

Special Populations and Alternatives

• For patients who cannot tolerate TMP-SMX, such as pregnant women, amoxicillin-clavulanate 20/5 mg/kg every 8 hours (maximum 1500/375 mg every 8 hours) can be used, although it is significantly less effective, as noted by the Journal of Microbiology, Immunology and Infection 8
• Children should receive the same weight-based TMP-SMX dosing as adults, according to the Journal of Microbiology, Immunology and Infection 8

Extended Duration Indications

• Treatment should be extended to 4-8 weeks or longer for central nervous system involvement, osteomyelitis or septic arthritis, as recommended by the Journal of Microbiology, Immunology and Infection 8
• For central nervous system involvement, TMP-SMX 8/40 mg/kg IV/PO every 12 hours up to 320/1600 mg should be added, as recommended by the Journal of Microbiology, Immunology and Infection 8

Critical Pitfalls to Avoid

• Ertapenem, azithromycin, and moxifloxacin should not be used due to inherent resistance, as noted by the British Journal of Pharmacology 9

Integration with Intensive Phase

• For melioidosis-induced septic shock, consider adding G-CSF 300 mg IV for 10 days during the intensive phase, as recommended by the Journal of Microbiology, Immunology and Infection 8

Management of Melioidosis with Deep-Seated Abscesses

Introduction and Treatment Duration

• The Infectious Diseases Society of America recommends an extended intensive phase duration of 4-8 weeks or longer of IV meropenem or imipenem for deep-seated abscesses, specifically because of deep-seated collections 10
• The American Thoracic Society suggests that immediate full-dose eradication therapy is required from day one to prevent the 13% relapse rate seen over 10 years, with full therapeutic doses of TMP-SMX 10

Eradication Phase and Dosing

• The Centers for Disease Control and Prevention recommends using full doses of TMP-SMX immediately, with dosing as follows: <40 kg: 160/800 mg (1 double-strength tablet) twice daily, 40-60 kg: 240/1200 mg (1.5 double-strength tablets) twice daily, and >60 kg: 320/1600 mg (2 double-strength tablets) twice daily, and adding folic acid 0.1 mg/kg up to 5 mg daily to prevent antifolate effects without compromising antimicrobial activity 10

Special Considerations

• For CNS involvement, the National Institute of Neurological Disorders and Stroke suggests using higher TMP-SMX dosing at 8/40 mg/kg IV/PO every 12 hours (up to 320/1600 mg) and extending duration to 4-8 weeks or longer 10
• For osteomyelitis or septic arthritis, the Infectious Diseases Society of America recommends extending both intensive and eradication phases 10

Alternative Regimens

• If true sulfonamide allergy or intolerance occurs, the American Academy of Allergy, Asthma, and Immunology suggests using amoxicillin-clavulanate 20/5 mg/kg every 8 hours (maximum 1500/375 mg every 8 hours) plus doxycycline 100 mg twice daily, although this combination is significantly less effective than TMP-SMX 10